Allergy Therapeutics (LON:AGY) Trading 11.1% Higher – Here’s What Happened

Allergy Therapeutics plc (LON:AGY)’s share price traded up 11.1% during trading on Monday . The company traded as high as GBX 6 ($0.08) and last traded at GBX 6 ($0.08). 952,562 shares traded hands during trading, an increase of 123% from the average session volume of 427,626 shares. The stock had previously closed at GBX 5.40 ($0.07).

Allergy Therapeutics Stock Performance

The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The firm has a market cap of £294.90 million, a PE ratio of -5.78, a P/E/G ratio of -30.70 and a beta of 1.40. The firm has a 50-day moving average price of GBX 6.36 and a two-hundred day moving average price of GBX 6.

Allergy Therapeutics (LON:AGY) last announced its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. Research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.